EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study ( COVER Study)

Qingxiu Xu iD, Xuan Yuan, Wang Liao, Hao Chen iD, Qing Jiang, Lin Yang, Jin Liu, Le Li iD, Nan Huang, Wenjing Li, Yaqi Yang, Dongxia Ma und 3 weitere

Allergy · 2026

DOI: 10.1111/all.70072 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Allergy, 2026. Verfasst von Qingxiu Xu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Antigens, Dermatophagoides, Pyroglyphidae, Rhinitis, Allergic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergen immunotherapy (AIT) is the only etiological treatment for allergic rhinitis (AR) patients, yet the impact of allergen sensitization patterns on AIT efficacy remains unclear. This study aimed to assess the effectiveness of subcutaneous immunotherapy (SCIT) using a native house dust mite (HDM) allergen extract in Chinese AR patients with diverse HDM sensitization patterns.

Methods

This prospective multicenter study across three allergy centers in China enrolled patients aged 5–65 diagnosed with HDM‐induced AR. Serum‐specific IgE testing for nine HDM components ( Der p1 , Der p2 , Der p23 , Der f1 , Der f2 , Der p5 , Der p7 , Der p10 , Der p21 ) categorized patients into two groups: Group A with sensitization limited to major allergen components and Group B with sensitization to minor components with or without major components. Both groups underwent 1 year of HDM SCIT (Allergopharma, Germany), whose efficacy was assessed using the visual analogue scale (VAS) and combined symptom medication scores (CSMS). Serum IgE and IgG4 levels against the nine HDM components were measured pre‐ and post‐treatment, and SCIT‐related adverse reactions were recorded.

Results

The study enrolled 168 patients, with 75 in Group A and 93 in Group B. Group B patients had higher asthma prevalence and elevated baseline HDM sIgE and total IgE levels. After 1 year, Group B showed significantly greater CSMS reduction (67.70% vs. 59.09%, p = 0.03) and VAS improvement (66.67% vs. 50.00%, p = 0.01) compared to Group A. Group A had increased new sensitization risk to minor allergens ( Der p5 , Der p7 , Der p21 ). No significant difference in SCIT efficacy was observed between patients with and without new sensitization. Both groups exhibited increased sIgG4 levels against all nine HDM allergens, with a more pronounced elevation of sIgG4 levels to Der p21 observed in Group B compared to Group A ( p = 0.02). SCIT‐related adverse reactions were comparable ( p > 0.05).

Conclusions

The native HDM allergen extract demonstrates efficacy in Chinese AR patients with varying sensitization patterns. It offers enhanced benefits for patients sensitized to minor allergens with or without major allergens of HDM, positioning it as the preferred option for individuals with AR. Trial Registration Chinese Clinical Trial Registry identifier: ChiCTR2300078642

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicAntigens, DermatophagoidesPyroglyphidaeRhinitis, AllergicAllergensHumansMaleAdultFemaleChildAdolescentAnimalsMiddle AgedChinaYoung AdultImmunoglobulin ETreatment OutcomeChild, PreschoolAgedProspective StudiesImmunoglobulin GEast Asian People

Stichwörter der Autor:innen

allergen immunotherapyallergic rhinitisefficacyhouse dust mitemolecular sensitization pattern

Substanzen

Antigens, DermatophagoidesImmunoglobulin EAllergensImmunoglobulin G

Autor:innen und Institutionen

  • Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, China.
  • Department of Pediatrics, Foshan Maternity & Child Healthcare Hospital, Foshan, China.
  • Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Qingxiu Xu, Hao Chen, Le Li, Zhihai Xie, Rongfei Zhu

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Xu, Q., Yuan, X., Liao, W., Chen, H., Jiang, Q., Yang, L., Liu, J., Li, L., Huang, N., Li, W., Yang, Y., Ma, D., Bai, J., Xie, Z., & Zhu, R. (2026). Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study ( COVER Study). Allergy. https://doi.org/10.1111/all.70072

Vancouver

Xu Q, Yuan X, Liao W, Chen H, Jiang Q, Yang L, et al. Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study ( COVER Study). Allergy. 2026. doi:10.1111/all.70072

BibTeX
@article{Xu2026,
  author = {Xu, Qingxiu and Yuan, Xuan and Liao, Wang and Chen, Hao and Jiang, Qing and Yang, Lin and Liu, Jin and Li, Le and Huang, Nan and Li, Wenjing and Yang, Yaqi and Ma, Dongxia and Bai, Jun and Xie, Zhihai and Zhu, Rongfei},
  title = {Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study ( COVER Study)},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70072}
}
Kostenlos starten →